SCHEMBL1099181

SCHEMBL1099181

Cc1ccc(Oc2ccc(S(=O)(=O)N(C)CC3NC(=O)NC3=O)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.42
HTT P42858 5/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
ALDH1A1 P00352 1/20 0.42
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
NR3C1 P04150 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
RXFP1 Q9HBX9 1/20 0.37
TSHR P16473 1/20 0.36
RECQL P46063 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GAA P10253 1/20 0.36
PTGES O14684 1/20 0.36
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108464 1.00 LMNA (0.42) LMNAHTTSMN1; SMN2ALDH1A1MMP2
SCHEMBL1098732 0.91 PGR (0.46) LMNAHTTSMN1; SMN2ALDH1A1MMP2
SCHEMBL1108549 0.91 PGR (0.44) LMNAHTTSMN1; SMN2ALDH1A1MMP2
SCHEMBL1100371 0.91 PGR (0.44) LMNAHTTSMN1; SMN2ALDH1A1MMP2
SCHEMBL1108503 0.91 PGR (0.46) LMNAHTTSMN1; SMN2ALDH1A1MMP2
SCHEMBL1108535 0.89 FFAR1 (0.45) LMNAHTTSMN1; SMN2ALDH1A1MMP2
SCHEMBL1100932 0.89 FFAR1 (0.45) LMNAHTTSMN1; SMN2ALDH1A1MMP2
SCHEMBL1101042 0.88 LMNA (0.40) LMNAHTTSMN1; SMN2ALDH1A1MMP2
SCHEMBL1108565 0.88 LMNA (0.40) LMNAHTTSMN1; SMN2ALDH1A1MMP2
SCHEMBL1099733 0.86 CACNA1H (0.43) LMNAHTTSMN1; SMN2ALDH1A1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
EP-1370537-B1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2010-10-13 EP disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 LMNA 2791/4885HTT 3958/4885SMN1; SMN2 1262/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 LMNA 2791/4885HTT 3958/4885SMN1; SMN2 1262/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 LMNA 2081/4885HTT 4646/4885SMN1; SMN2 1982/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 LMNA 2465/4885HTT 4139/4885SMN1; SMN2 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.